Core Insights - Daxor Corporation will host an investor conference call on March 6, 2025, at 4:30 p.m. ET to review financial results and corporate developments [1][2] - The call will feature President and CEO Michael Feldschuh and CFO Robert Michel, followed by a Q&A session for investors [2] - Daxor is recognized as a leader in blood volume measurement technology, with its BVA-100™ being the only FDA-cleared diagnostic blood test for quantifying blood volume status [3] Company Overview - Daxor Corporation focuses on blood volume testing innovation and has performed over 65,000 tests at leading hospital centers in the U.S., significantly impacting patient outcomes in heart failure and critical care [3] - The company is involved in ongoing trials for heart failure treatment supported by the NIH and is developing analyzers for combat casualty care in collaboration with the U.S. Department of Defense [3] - Daxor's mission is to enhance healthcare through optimal fluid management via blood volume analysis, aiming for optimal blood volume for all patients [3]
Daxor Corporation to Host Investor Conference Call to Discuss Fiscal Year 2024 Financial Results and Provide a Corporate Update on March 6, 2025